Obstetric Haemorrhage - PPH and Massive Transfusion

Quick Answer

What is postpartum haemorrhage (PPH)?

Primary PPH is defined as blood loss ≥500 mL within 24 hours of vaginal delivery or ≥1000 mL following cesarean section. Major PPH is blood loss >1000 mL or blood loss accompanied by signs of hypovolemia. PPH affects 5-15% of deliveries and is the leading cause of maternal mortality worldwide, accounting for 27% of maternal deaths globally. [1,2]

Causes - The "4 Ts":

Immediate management priorities:

1. Call for help - Activate PPH protocol and massive transfusion protocol if indicated
2. Two large-bore IVs (14-16G) + arterial line
3. Blood products - Type and crossmatch 4-6 units; give O-negative blood if delay
4. Tranexamic acid - 1 g IV over 10 minutes (within 3 hours of delivery; reduces mortality by 30%)
5. Uterine massage and oxytocin 5-10 units slow IV or 10-20 units/hr infusion
6. Bimanual compression while preparing for operative management
7. Second-line uterotonics - Ergometrine 0.25 mg IM (avoid if hypertensive), carboprost 250 μg IM q15min (max 2 mg), misoprostol 600-1000 μg PR/SL

Massive transfusion protocol (blood loss >1500 mL or >30% blood volume):

Target thresholds in massive hemorrhage:

• Hemoglobin >80 g/L
• Platelets >50 × 10⁹/L (>80-100 for neuraxial)
• PT/APTT <1.5× ULN
• Fibrinogen >2 g/L
• Ionized calcium >1.1 mmol/L
• pH >7.2, lactate <4 mmol/L

Surgical/interventional management:

• Examination under anesthesia and repair of trauma
• Uterine balloon tamponade (Bakri balloon)
• Uterine compression sutures (B-Lynch, Hayman)
• Uterine artery embolization
• Internal iliac (hypogastric) artery ligation
• Hysterectomy (last resort, but do not delay)

Clinical Pearl: In PPH, the most common error is underestimating blood loss. Visual estimation typically underestimates by 30-50%. Use calibrated drapes, weigh blood-soaked items (1 mL blood ≈ 1 g), and monitor for hemodynamic compensation (tachycardia precedes hypotension). The "lethal triad" of hypothermia, acidosis, and coagulopathy develops rapidly - prevent it with active warming, blood product replacement, and early TXA.

---

Clinical Overview

Definition and Classification

Primary PPH (within 24 hours of delivery):

• Minor PPH: 500-1000 mL blood loss
• Major PPH: >1000 mL blood loss
• Severe PPH: >2000 mL or requiring transfusion >5 units or causing hemodynamic instability

Secondary PPH (24 hours to 12 weeks postpartum):

• Occurs in 1-2% of deliveries
• Usually due to retained placental tissue, infection, or abnormal placental site involution

Massive Obstetric Hemorrhage (various definitions):

• Loss of >1500 mL blood
• Loss of >30% circulating blood volume
• Transfusion requirement >4 units RBC in 1 hour
• Transfusion requirement >8 units RBC total
• Hemodynamic instability requiring vasopressors [3,4]

Epidemiology

High-risk groups:

• Indigenous women (Australia/NZ): 2-3× higher rates of severe PPH
• Developing countries: 99% of PPH-related maternal deaths occur here
• Grand multiparity: Risk increases with parity >4
• Multiple pregnancy: 4-5× increased risk

Pathophysiology

Normal Hemostasis in Delivery:

Third stage mechanisms:

1. Uterine contraction - Reduces blood flow to intervascular spaces
2. Living ligatures - Contraction of myometrium compresses vessels
3. Placental separation - Shearing at spongy layer; compression at decidua basalis
4. Clot formation - Local coagulation cascade activation

Pathophysiology of PPH by Cause:

Tone (Atony) - 70-80%:

• Failure of myometrial contraction → inability to compress placental bed vessels
• Risk factors: Prolonged labor, multiple pregnancy, polyhydramnios, uterine overdistension, chorioamnionitis, general anesthesia with volatile agents, magnesium sulfate therapy

Trauma - 15-20%:

• Genital tract lacerations (cervix, vagina, perineum)
• Uterine rupture (previous scar, obstructed labor)
• Uterine inversion (excessive cord traction, fundal pressure)
• Hematomas (vulvar, vaginal, retroperitoneal)
• Instrumental delivery (forceps, vacuum)

Tissue - 5-10%:

• Retained placental fragments
• Placenta accreta spectrum (abnormal trophoblastic invasion)
• Succenturiate lobe
• Morbidly adherent placenta

Thrombin - 1-2%:

• Pre-existing coagulopathy (von Willebrand disease, ITP, hemophilia carriers)
• Acquired coagulopathy (DIC from abruption, amniotic fluid embolism, sepsis)
• Anticoagulant therapy
• Thrombocytopenia (gestational, ITP, TTP/HUS)

Physiologic Response to Hemorrhage:

Coagulopathy in PPH:

• Dilutional coagulopathy - Replacement with crystalloid/colloid without adequate blood products
• Consumptive coagulopathy - DIC from placental abruption, AFE, sepsis
• Hypothermia - Impairs coagulation cascade enzyme function
• Acidosis - Reduces factor activity and platelet function
• Hypocalcemia - Citrate toxicity from massive transfusion

---

Clinical Presentation and Assessment

Signs and Symptoms

Early signs (compensated shock):

• Tachycardia (>100 bpm) - earliest and most sensitive sign
• Narrow pulse pressure
• Anxiety, restlessness
• Cool, clammy skin
• Delayed capillary refill (>2 seconds)
• Decreased urine output (<30 mL/hr)

Late signs (decompensated shock):

• Hypotension (systolic <90 mmHg, MAP <65 mmHg)
• Altered mental status (confusion, agitation, obtundation)
• Oliguria or anuria
• Signs of DIC (oozing from IV sites, petechiae)
• Hypothermia
• Metabolic acidosis

Red flags requiring immediate intervention:

• Blood loss >1000 mL with ongoing bleeding
• Hemodynamic instability (systolic BP <90, MAP <65, HR >120)
• Altered consciousness
• Placental abruption with fetal compromise
• Suspected uterine inversion or rupture
• Signs of DIC (coagulopathy)
• Concealed bleeding (rapid intraperitoneal or retroperitoneal hemorrhage)

Blood Loss Estimation

Methods and limitations:

Shock Index in Obstetric Hemorrhage:

• Normal pregnancy: 0.7-0.8
• Mild shock: 0.9-1.1
• Moderate shock: 1.1-1.4
• Severe shock: >1.4

Investigation and Monitoring

Immediate investigations:

Bedside point-of-care testing:

• TEG/ROTEM - Whole blood viscoelastic testing for rapid coagulation assessment
• i-STAT - Arterial blood gas with ionized calcium
• Hemocue - Bedside hemoglobin measurement

Hemodynamic monitoring:

• Arterial line for continuous BP monitoring
• Central venous access for vasopressor administration if needed
• Urinary catheter for hourly urine output
• Consider advanced monitoring (PiCCO, pulmonary artery catheter) in refractory cases

---

Management

Immediate Resuscitation

Call for help and organize team:

• Activate PPH protocol/massive transfusion protocol
• Obstetric team, anesthetic team, hematology, blood bank, interventional radiology
• Two-way communication with blood bank

ABCDE approach:

Airway:

• High-flow oxygen (10-15 L/min via facemask)
• If decreased consciousness or respiratory distress: Prepare for intubation
• RSI if hemodynamically unstable with full stomach risk

Breathing:

• Monitor SpO2, respiratory rate, auscultation
• Chest X-ray if pulmonary edema or aspiration suspected
• Mechanical ventilation if respiratory failure

Circulation:

• Two large-bore IV cannulae (14-16G)
• Arterial line (radial or femoral)
• Warmed crystalloid initial resuscitation (avoid excessive crystalloid)
• Blood products as per massive transfusion protocol
• Active warming (forced air warming, warmed fluids)

Drugs:

• Tranexamic acid 1 g IV over 10 minutes (repeat 1 g after 30 min if ongoing bleeding)
• Oxytocin 5-10 units slow IV or infusion 10-40 units/hr
• Second-line uterotonics as needed
• Vasopressors if hypotension persists despite fluids (phenylephrine, noradrenaline)

Exposure/Environment:

• Full exposure to identify all bleeding sites
• Active warming to prevent hypothermia
• Consider lower limb compression stockings

Uterine Atony Management

Stepwise approach:

Step 1: Pharmacologic (simultaneous with resuscitation):

Step 2: Mechanical:

• Uterine massage and bimanual compression
• Intrauterine balloon tamponade (Bakri balloon)

Step 3: Surgical (if above fails):

• Examination under anesthesia (repair lacerations)
• Uterine compression sutures (B-Lynch, Hayman, multiple square sutures)
• Uterine artery ligation (O'Leary sutures)
• Internal iliac (hypogastric) artery ligation
• Uterine artery embolization (interventional radiology)
• Hysterectomy (peripartum or cesarean)

B-Lynch Suture Technique:

• Compression suture that "doubles" the uterus
• 2-0 or 0 chromic catgut on large needle
• Enters through lower segment anterior, exits posterior, over fundus, re-enters posterior, exits anterior, tied at lower segment
• Multiple parallel sutures can be placed
• Preserves uterus and fertility

Tranexamic Acid (TXA)

Mechanism:

• Synthetic lysine analog
• Competitive inhibitor of plasminogen activation
• Blocks conversion of plasminogen to plasmin
• Prevents fibrin clot breakdown (stabilizes existing clots)

Evidence (WOMAN Trial 2017):

• 20,060 women with PPH in 21 countries
• TXA reduced death due to bleeding by 30% if given within 3 hours
• NNT to prevent one death = 267 (for PPH >500 mL)
• No increased thrombotic events
• No benefit if given >3 hours after delivery

Dosing:

• 1 g IV over 10 minutes (slow to avoid hypotension)
• Repeat 1 g after 30 minutes if ongoing bleeding
• Can be given IM if IV access unavailable

Contraindications/caution:

• Active intravascular clotting (DIC with thrombosis)
• History of thromboembolic disease (relative)
• Color vision disturbances (very rare)
• Subarachnoid hemorrhage (potential cerebral edema)

Massive Transfusion Protocol (MTP)

Activation criteria:

• Blood loss >1500-2000 mL
• Blood loss >30% circulating volume
• Hemodynamic instability with ongoing bleeding
• Anticipated transfusion >4-6 units RBC

Blood product ratios:

Modified MTP for Obstetrics:

• May use FFP:RBC ratio 1:2 initially (less FFP required due to normal baseline coagulation)
• Cryoprecipitate/fibrinogen concentrate prioritized (fibrinogen falls first in obstetric hemorrhage)
• Higher platelet thresholds (aim >75-100 × 10⁹/L for potential neuraxial)

Monitoring during MTP:

• FBC, coagulation, fibrinogen every 30-60 minutes
• Viscoelastic testing (TEG/ROTEM) if available
• Ionized calcium every 30 minutes (citrate toxicity)
• Blood gas for pH, lactate
• Temperature (maintain >36°C)

Complications of massive transfusion:

• Hypothermia - Impairs coagulation
• Acidosis - Impairs coagulation
• Hypocalcemia - Citrate chelates calcium
• Hyperkalemia - From stored blood
• TRALI - Transfusion-related acute lung injury
• TACO - Transfusion-associated circulatory overload
• Infection risk - Viral, bacterial contamination

Coagulation Management

Fibrinogen in obstetric hemorrhage:

• Fibrinogen falls early and disproportionately (consumption + hemodilution)
• Target: >2 g/L (some centers >3 g/L in active bleeding)
• Replacement: Cryoprecipitate (10 units) or fibrinogen concentrate (3-4 g)
• Each 1 g fibrinogen raises level by ~0.25-0.5 g/L

Recombinant Factor VIIa:

• Last resort for refractory coagulopathic bleeding
• Dose: 60-90 mcg/kg IV
• Requires adequate fibrinogen (>1 g/L) and platelets (>20 × 10⁹/L) to be effective
• Risk of thrombosis (DIC, PE, arterial thrombosis)
• Expensive; not first-line

Prothrombin complex concentrate (PCC):

• Contains factors II, VII, IX, X
• May be used if FFP unavailable or contraindicated
• Limited obstetric data

Anesthetic Management

Regional anesthesia considerations:

• Epidural catheter in situ can be topped up for operative procedures (instrumental delivery, exploration, repair)
• CAUTION: Hypotension from sympathetic blockade can worsen hemorrhage
• Ensure adequate volume resuscitation before topping up
• Consider GA if hemodynamically unstable

General anesthesia for PPH:

Indications:

• Hemodynamic instability
• Failed regional
• Need for rapid surgical control
• Coagulopathy contraindicating neuraxial
• Patient refusal of regional

Technique:

• RSI with cricoid pressure (full stomach risk)
• Pre-oxygenation 3-5 minutes
• Induction: Ketamine 1-1.5 mg/kg (maintains BP) or etomidate 0.3 mg/kg; avoid propofol if hypotensive
• Airway: Video laryngoscopy if available; difficult airway common in pregnancy
• Maintenance: Low-dose volatile + opioid + muscle relaxant
• Monitoring: Arterial line, central line if vasopressors needed, temperature, urine output
• Reversal: Sugammadex preferred (faster recovery)

Intraoperative priorities:

• Maintain uterine displacement (left lateral tilt)
• Blood product administration (MTP)
• Active warming (forced air, fluid warmers)
• Calcium replacement (ionized calcium >1.1 mmol/L)
• Second anesthetist or OT nurse dedicated to blood products
• Cell salvage if available (safe in obstetrics with leukodepletion filter)

Postoperative:

• HDU/ICU admission
• Continue blood products until bleeding controlled
• Monitor for re-bleeding, coagulopathy, hypothermia
• Thromboprophylaxis once bleeding controlled (LMWH 6-12 hours post-surgery if hemostasis achieved)

Special Scenarios

Placenta Accreta Spectrum:

Anesthetic approach:

• Planned delivery in high-volume center with blood products available
• GA preferred (hemorrhage anticipated, potential for bladder/ureter involvement)
• Arterial and central venous access
• Interventional radiology on standby (prophylactic balloon catheters)
• Cell salvage
• Multidisciplinary team (urology if percreta suspected)

Uterine Inversion:

• Obstetric emergency; presents with pain, bleeding, shock out of proportion to blood loss (neurogenic shock from vagal stimulation)
• Immediate vagal response → bradycardia, hypotension
• Management: Urgent manual replacement (Johnson maneuver) under GA with tocolysis (terbutaline, magnesium, or halogenated agents)
• If manual replacement fails: Laparotomy with Huntington or Haultain procedure

Amniotic Fluid Embolism (AFE):

• Sudden cardiovascular collapse, hypoxia, coagulopathy during labor/delivery or immediately postpartum
• Diagnosis of exclusion; presents like PPH with DIC
• Management: Supportive (oxygenation, vasopressors, blood products for DIC)
• High mortality (20-60%); ICU admission essential

---

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Women:

Indigenous women in Australia experience 2-3 times higher rates of PPH and 4-5 times higher rates of severe maternal morbidity from hemorrhage compared to non-Indigenous women. [7,8]

Contributing factors:

1. Geographic remoteness: Limited access to specialist obstetric services, blood products, and surgical facilities
2. Higher baseline risk factors: Increased rates of anemia, multiple gestation, grand multiparity, and previous PPH
3. Delayed recognition and intervention: Cultural barriers to seeking care, communication challenges, institutional racism
4. Systemic issues: Transport and retrieval challenges, resource limitations in remote facilities

Clinical management considerations:

Prevention strategies:

• Active management of third stage for all deliveries in high-risk populations
• Pre-delivery anemia correction (iron supplementation, IV iron if needed)
• Identification of high-risk cases with delivery planning at appropriate facilities

Remote area considerations:

• Early activation of retrieval services (RFDS) for high-risk pregnancies
• Telemedicine support for remote practitioners managing PPH
• Pre-positioning of blood products (O-negative, plasma) in remote facilities
• Clear protocols for stabilization before transfer

Cultural safety:

• Involvement of Aboriginal Health Workers in care and communication
• Recognition of family decision-making structures
• Use of interpreter services where needed
• Understanding of cultural perspectives on blood transfusion (some cultural beliefs around blood as life force)

Māori Women (Aotearoa New Zealand):

Similar disparities exist with higher rates of severe maternal morbidity from PPH. [9,10]

Whānau-centered approaches:

• Involvement of whānau in resuscitation decisions
• Cultural liaison support during emergency situations
• Recognition that maternal outcomes affect the entire whānau structure
• Post-hemorrhage care that addresses both physical recovery and psychological impact on mother and family

Key principle: PPH management in Indigenous populations requires not only clinical excellence but also systems that address geographic barriers, ensure culturally safe care, and actively work to reduce the disparities in maternal outcomes through prevention, early recognition, and rapid escalation of care.

---

ANZCA Exam Focus

High-Yield Topics

Written Examination:

• Blood product ratios in massive transfusion (1:1:1 vs. modified for obstetrics)
• Pharmacology of uterotonics (oxytocin, ergometrine, carboprost, misoprostol)
• Tranexamic acid mechanism, dosing, and WOMAN trial evidence
• Coagulopathy management (fibrinogen targets, cryoprecipitate vs. concentrate)
• PPH causes and stepwise management algorithm

Viva Voce:

• Immediate management of catastrophic PPH
• Decision-making: Regional vs. GA in the bleeding patient
• Massive transfusion protocol activation and coordination
• Interpretation of coagulation results and TEG/ROTEM
• Ethical scenarios: Jehovah's Witness patient with PPH

Common Exam Scenarios

Scenario 1: Uterine Atony after Vaginal Delivery

• 35-year-old G4P3, vaginal delivery of 4.2 kg infant
• Prolonged second stage (3 hours), augmentation with oxytocin
• Estimated blood loss 1500 mL, ongoing uterine atony
• HR 120, BP 95/60, pale, clammy

Key discussion points:

• Resuscitation priorities (2 large IVs, blood products, TXA)
• Stepwise uterotonic escalation
• Mechanical interventions (massage, bimanual compression, Bakri balloon)
• Surgical options if medical management fails

Scenario 2: Placenta Accreta at Elective Cesarean

• 38-year-old G3P2 with previous 2 cesarean sections
• Placenta previa and suspected accreta on MRI
• Scheduled for cesarean at 36 weeks

Key discussion points:

• Preoperative preparation (blood products, cell salvage, interventional radiology)
• Anesthetic technique (GA preferred)
• Multidisciplinary team planning
• Hysterectomy considerations

Scenario 3: Coagulopathic PPH

• 29-year-old with placental abruption
• Massive hemorrhage, requiring 10 units RBC
• INR 2.2, APTT 58, fibrinogen 0.8 g/L, platelets 45 × 10⁹/L
• Ongoing bleeding despite uterine atony controlled

Key discussion points:

• Massive transfusion protocol ratios
• Cryoprecipitate/fibrinogen concentrate dosing
• Calcium replacement for citrate toxicity
• Consideration of recombinant Factor VIIa
• ICU admission and ongoing management

Key Pharmacology

Tranexamic Acid:

• Synthetic lysine analog, competitive plasminogen inhibitor
• Dose: 1 g IV over 10 minutes, repeat after 30 minutes
• Reduces mortality when given within 3 hours of delivery (WOMAN trial)
• Side effects: GI upset, rarely seizures, color vision changes

Uterotonics:

• Oxytocin: Acts on oxytocin receptors → uterine contraction; 5-10 units IV (slow) or 10-40 units/hr infusion
• Ergometrine: Ergot alkaloid, potent sustained contraction; 0.25 mg IM (contraindicated in hypertension)
• Carboprost: PGF2α analog; 250 μg IM q15min (max 2 mg); avoid in asthma
• Misoprostol: PGE1 analog; 600-1000 μg PR/SL; thermostable, inexpensive

---

Assessment Content

SAQ 1: Management of Major PPH (20 marks)

Question:

A 32-year-old G2P1 has just delivered a 4.2 kg infant vaginally after a prolonged second stage (2.5 hours) and vacuum-assisted delivery. She has had an estimated blood loss of 1200 mL. Her vital signs are:

• BP: 88/52 mmHg
• HR: 128 bpm
• SpO2: 96% on room air
• Temperature: 35.8°C

On examination, the uterus is boggy and atonic. There is ongoing moderate vaginal bleeding. Blood results show:

• Hb: 82 g/L
• Platelets: 155 × 10⁹/L
• PT: 14 seconds (control 12)
• APTT: 38 seconds (control 32)
• Fibrinogen: 1.2 g/L

a) Outline your immediate management priorities for this patient. (8 marks)

b) Describe the role of tranexamic acid in postpartum hemorrhage, including the evidence base, mechanism of action, dosing, and timing considerations. (6 marks)

c) If bleeding persists despite optimal medical management, describe the stepwise surgical and interventional options available. (6 marks)

---

Model Answer:

a) Immediate management priorities (8 marks):

b) Tranexamic acid (6 marks):

Evidence base:

• WOMAN Trial (2017): 20,060 women in 21 countries; TXA reduced death due to bleeding by 30% (RR 0.81) when given within 3 hours of delivery
• No benefit if given >3 hours after delivery
• NNT to prevent one death = 267
• No increase in thrombotic events

Mechanism:

• Synthetic lysine analog
• Competitive inhibitor of plasminogen activation
• Blocks conversion of plasminogen to plasmin
• Prevents fibrinolysis and stabilizes clots

Dosing:

• 1 g IV over 10 minutes (slow to avoid hypotension)
• Repeat 1 g after 30 minutes if ongoing bleeding
• Can be given IM if no IV access

Timing:

• CRITICAL: Must be given within 3 hours of delivery for mortality benefit
• Earlier administration more effective
• Can be given at same time as first-line uterotonics

Contraindications:

• Active intravascular thrombosis
• History of thromboembolism (relative)
• Subarachnoid hemorrhage

c) Stepwise surgical/interventional options (6 marks):

Note: If interventional radiology available and patient stable, embolization may be considered before laparotomy. In unstable patient, proceed directly to laparotomy with surgical options.

---

SAQ 2: Massive Transfusion in Obstetrics (15 marks)

Question:

A 28-year-old woman at 38 weeks gestation presents with major placental abruption and intrauterine fetal death. She undergoes emergency cesarean section under general anesthesia. Intraoperatively, she develops massive hemorrhage with blood loss of approximately 4 L. Her current blood results are:

• Hb: 62 g/L
• Platelets: 48 × 10⁹/L
• PT: 22 seconds (control 12)
• APTT: 68 seconds (control 32)
• Fibrinogen: 0.6 g/L
• Ionized calcium: 0.82 mmol/L
• pH: 7.18
• Lactate: 6.2 mmol/L

She has already received 8 units of O-negative red blood cells and 4 units of fresh frozen plasma.

a) What are your blood product priorities at this stage? Justify your choices with target levels. (6 marks)

b) Outline the specific complications of massive transfusion that you need to prevent or manage in this patient. (5 marks)

c) What additional pharmacological or procedural interventions may be considered if bleeding persists despite optimal blood product replacement? (4 marks)

---

Model Answer:

a) Blood product priorities (6 marks):

Specific actions:

1. Cryoprecipitate 10 units or fibrinogen concentrate 4 g - priority (fibrinogen critically low)
2. Calcium chloride 1 g IV or calcium gluconate 2 g IV - urgent (citrate toxicity)
3. Platelets 1 apheresis unit (or 6-10 pooled units) - thrombocytopenia
4. Continue RBC:FFP in 1:1 ratio
5. Check ionized calcium, fibrinogen every 30 minutes

b) Complications of massive transfusion (5 marks):

c) Additional interventions if bleeding persists (4 marks):

---

Viva Scenario: PPH with Jehovah's Witness Patient

Setting: Clinical viva (10 minutes)

Scenario:

"A 34-year-old Jehovah's Witness patient has delivered her third baby vaginally and has developed severe uterine atony. She has lost approximately 1500 mL of blood and continues to bleed. Her hemoglobin has fallen from 105 g/L antenatally to 68 g/L. She is pale, tachycardic (HR 125), and hypotensive (BP 92/58). She has signed an advance directive refusing all blood transfusions, including fresh frozen plasma and platelets."

Examiner-Candidate Dialogue:

Examiner: "How would you approach the management of this patient?"

Candidate: "This is a challenging scenario requiring respect for patient autonomy while attempting to preserve life. My approach would be:"

1. Respect autonomy:

   • Confirm the patient has capacity and understands the consequences of refusal
   • Ensure advance directive is valid, witnessed, and contemporaneous
   • Document conversation clearly
   • Inform senior colleagues and hospital legal team

2. Maximize non-blood alternatives:

3. Escalation:
   • Early involvement of senior obstetrician, hematologist, hospital ethics committee
   • Consider patient request for "bloodless" surgery team
   • If patient loses capacity and no valid advance directive, may treat in best interests (legal advice needed)

Examiner: "What specific pharmacological agents would you use in this scenario?"

Candidate:

Examiner: "What would you do if the patient became unconscious and you were unable to obtain consent for life-saving transfusion?"

Candidate:

"This raises complex legal and ethical issues that vary by jurisdiction. My approach would be:"

1. Immediate actions:

   • Continue maximal non-blood therapy
   • Check if valid advance directive exists and is accessible
   • Attempt to contact next of kin/patient's representative
   • Consult hospital legal team and ethics committee urgently

2. Legal principles (Australia/NZ context):

   • Valid advance directive refusing treatment must be respected even if life-threatening
   • If no valid directive and patient lacks capacity, treat in best interests
   • Emergency doctrine allows treatment to preserve life if patient unable to consent and no directive known
   • Each case requires individual legal advice

3. Documentation:

   • Record all discussions, interventions, and rationale
   • Document that treatment is in patient's best interests if proceeding
   • Ensure senior clinician involvement in decision-making

4. Post-event:

   • Debrief with team
   • Review case for learning
   • Support staff who may be distressed by outcome

Examiner: "How does cell salvage work, and why might it be acceptable to Jehovah's Witnesses when banked blood is not?"

Candidate:

"Cell salvage (intraoperative blood recovery) involves:"

1. Process:

   • Blood lost during surgery is suctioned into a collection reservoir
   • Anticoagulant (usually heparin or citrate) added
   • Blood is filtered, washed, centrifuged to remove plasma and debris
   • Concentrated RBCs (hematocrit ~60%) reinfused

2. Acceptability to Jehovah's Witnesses:

   • Many accept cell salvage because it involves their own blood that remains in continuous circuit with their body
   • Interpretation of biblical injunction against "eating blood" varies - some view reinfusion of own blood as acceptable
   • Key is maintaining continuity with body (closed circuit)
   • Must discuss with individual patient - some may still refuse
   • Use of leukodepletion filter may increase acceptability

3. Contraindications in obstetrics:

   • Theoretical risk of amniotic fluid embolism if amniotic fluid not adequately removed
   • Modern systems with leukodepletion filters reduce this risk
   • Generally considered safe when used appropriately

---

References

1. Carroli G, Cuesta C, Abalos E, Gulmezoglu AM. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):999-1012. PMID: 18819848

2. Knight M; UK Obstetric Surveillance System (UKOSS). Peripartum hysterectomy in the UK: management and outcomes of the associated haemorrhage. BJOG. 2007;114(11):1380-1387. PMID: 17617017

3. Bonnar J. Massive obstetric haemorrhage. Baillieres Best Pract Res Clin Obstet Gynaecol. 2000;14(1):1-18. PMID: 10822152

4. Rizvi F, Mackey R, Barrett T, et al. Successful reduction of massive postpartum haemorrhage by use of guidelines and staff education. BJOG. 2004;111(5):495-498. PMID: 15104625

5. Stones RW, Paterson CM, Saunders NJ. Risk factors for major obstetric haemorrhage. Eur J Obstet Gynecol Reprod Biol. 1993;48(1):15-18. PMID: 8467651

6. Combs CA, Murphy EL, Laros RK Jr. Factors associated with postpartum hemorrhage with vaginal birth. Obstet Gynecol. 1991;77(1):69-76. PMID: 1984230

7. Australian Institute of Health and Welfare. Australia's Mothers and Babies 2018. Canberra: AIHW; 2020. Perinatal statistics series no. 35. PMID: N/A

8. Kildea S, Gao Y, Rolfe M, et al. Remote links: redesigning maternity care for Aboriginal women from remote communities. Med J Aust. 2016;205(11):498-499. PMID: 27913748

9. Ministry of Health NZ. Report on Maternity 2017. Wellington: Ministry of Health; 2019. PMID: N/A

10. Robson SJ, Cameron CA, Roberts CL. Birth outcomes for teenage women in New South Wales, 1998-2003. Aust N Z J Obstet Gynaecol. 2006;46(4):305-310. PMID: 16866783

11. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105-2116. PMID: 28456509

12. Shakur H, Beaumont D, Pavord S, et al. Antifibrinolytic drugs for treating primary postpartum haemorrhage. Cochrane Database Syst Rev. 2018;2:CD012964. PMID: 29446165

13. Gayat E, Resche-Rigon M, Morel O, et al. Predictive factors of advanced interventional procedures and maternal outcomes in women with severe postpartum hemorrhage. J Matern Fetal Neonatal Med. 2013;26(17):1705-1711. PMID: 23789846

14. Clark SL, Phelan JP, Yeh SY, et al. Hypogastric artery ligation for obstetric hemorrhage. Obstet Gynecol. 1985;66(3):353-356. PMID: 4022497

15. B-Lynch C, Coker A, Lawal AH, et al. The B-Lynch surgical technique for the control of massive postpartum haemorrhage: an alternative to hysterectomy? Five cases reported. Br J Obstet Gynaecol. 1997;104(3):372-375. PMID: 9088270

16. Hayman RG, Arulkumaran S, Steer PJ. Uterine compression sutures: surgical management of postpartum hemorrhage. Obstet Gynecol. 2002;99(3):502-506. PMID: 11864627

17. Danso D, Reginald PW. Maternal mortality from 'major' postpartum haemorrhage at the Korle-Bu Teaching Hospital: an unusual triennial experience. Trop Doct. 2001;31(3):138-140. PMID: 11459375

18. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost. 2007;5(2):266-273. PMID: 17096717

19. de Lloyd L, Bovington R, Kaye A, et al. Standard haemostatic tests following major obstetric haemorrhage. Int J Obstet Anesth. 2011;20(2):135-141. PMID: 21316702

20. Butwick AJ, Goodnough LT. Transfusion and coagulation management in major obstetric hemorrhage. Curr Opin Anaesthesiol. 2015;28(3):275-284. PMID: 25827198

21. McLintock C, James AH. Obstetric hemorrhage. J Thromb Haemost. 2011;9(8):1441-1451. PMID: 21624030

22. Cortet M, Deneux-Tharaux C, Dupont C, et al. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. Br J Anaesth. 2012;108(6):984-989. PMID: 22493596

23. Collins PW, Lilley G, Bruynseels D, et al. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood. 2014;124(11):1727-1736. PMID: 24923275

24. Ahmed S, Harrity C, Johnson S, et al. The efficacy of fibrinogen concentrate compared with cryoprecipitate in major obstetric haemorrhage - an observational study. Transfus Med. 2012;22(5):344-349. PMID: 22845738

25. Collins PW, Solomon C, Sutor K, et al. Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate. Br J Anaesth. 2014;113(4):585-595. PMID: 24859966

26. Nascimento B, Goodnough LT, Levy JH. Cryoprecipitate or fibrinogen concentrate for fibrin replacement in acquired bleeding disorders? Curr Opin Anaesthesiol. 2014;27(6):597-603. PMID: 25250749

27. McDonnell NJ, Browning RM, Paech MJ. Extreme morbid obesity and labour anaesthesia: a case series. Int J Obstet Anesth. 2011;20(2):138-144. PMID: 21316703

28. Waters JH, Biscotti C, Potter PS, et al. Amniotic fluid removal during cell salvage in the cesarean section patient. Anesthesiology. 2000;92(6):1531-1536. PMID: 10839904

29. Thomas J, Marx G. Modern approaches to the management of severe obstetric hemorrhage. Curr Opin Anaesthesiol. 2016;29(3):292-299. PMID: 27023644

30. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295(2):227-228. PMID: 16403931

31. Franchini M, Lippi G, Franchi M. The use of recombinant activated factor VII in obstetric and gynaecological haemorrhage. BJOG. 2007;114(1):8-15. PMID: 17169014

32. Alfirevic Z, Elbourne D, Pavord S, et al. Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2008. Obstet Gynecol. 2012;120(6):1270-1278. PMID: 23168754

33. Leighton BL, Wall MH, Lockhart EM, et al. Use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reports. Anesthesiology. 2011;115(5):1201-1208. PMID: 21918388

34. Dildy GA III, Scott JR, Saffer CS, Belfort MA. An effective pressure pack for severe pelvic hemorrhage. Obstet Gynecol. 2006;108(5):1222-1226. PMID: 17077238

35. Plante AF, Tuuli MG, Della Torre M, et al. Peripartum hysterectomy: risk factors, management, and outcomes. Am J Perinatol. 2017;34(5):441-446. PMID: 27583479

36. Baskett TF. Emergency obstetric hysterectomy. J Obstet Gynaecol. 2003;23(4):353-355. PMID: 12850854

37. Shellhaas CS, Gilbert S, Landon MB, et al. The frequency and complication rates of hysterectomy accompanying cesarean delivery. Obstet Gynecol. 2009;114(2 Pt 1):224-229. PMID: 19622946

38. Kacmar RM, Mhyre JM, Scavone BM, et al. The use of postpartum hemorrhage protocols in United States academic obstetric anesthesia units. Anesth Analg. 2014;119(4):906-910. PMID: 25050552

39. Shields LE, Smalarz K, Reffigee L, et al. Comprehensive maternal hemorrhage protocols improve patient safety and reduce utilization of blood products. Am J Obstet Gynecol. 2011;205(4):368.e1-368.e8. PMID: 21864830

40. Main EK, Goffman D, Scavone BM, et al. National Partnership for Maternal Safety: Consensus Bundle on Obstetric Hemorrhage. Anesth Analg. 2015;121(6):1420-1427. PMID: 26485668

41. Lalonde A, Daviss BA. Joint statement from the International Confederation of Midwives (ICM) and the International Federation of Gynaecology and Obstetrics (FIGO) and the International Association of Obstetricians and Gynecologists (IAOG). Int J Gynaecol Obstet. 2006;94(3):249. PMID: 16879867

42. Berg CJ, Harper MA, Atkinson SM, et al. Preventability of pregnancy-related deaths: results of a state-wide review. Obstet Gynecol. 2005;106(6):1228-1234. PMID: 16319256

43. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998-2005. Obstet Gynecol. 2010;116(6):1302-1309. PMID: 21099595

44. Callaghan WM, Kuklina EV, Berg CJ. Trends in postpartum hemorrhage: United States, 1994-2006. Am J Obstet Gynecol. 2010;202(4):353.e1-353.e6. PMID: 20350641

45. Kramer MS, Berg C, Abenhaim H, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. Am J Obstet Gynecol. 2013;209(5):449.e1-449.e7. PMID: 23871955

46. Knight M, Callaghan WM, Berg C, et al. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. BMC Pregnancy Childbirth. 2009;9:55. PMID: 19943928

47. Fawcus S, Moodley J. Postpartum haemorrhage associated with caesarean section and caesarean hysterectomy. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):1069-1082. PMID: 18819857

48. Fawcus SR, van Coeverden de Groot HA, Isaacs S. A 50-year audit of maternal mortality in the Peninsula Maternity Hospital, Cape Town (1963-2012). S Afr Med J. 2016;106(4):396-403. PMID: 27121015

49. Fawcus S, Moodley J. Maternal mortality and severe maternal morbidity from acute uterine inversion in South Africa. S Afr Med J. 2013;103(11):884. PMID: 24148144

50. Krapp M, Baselski V, Heling KS, et al. Fibrinogen concentration in maternal plasma, amniotic fluid and venous cord blood at the time of delivery. J Perinat Med. 2001;29(5):415-421. PMID: 11724115

51. Karlsson O, Jeppsson A, Hellgren M. Major obstetric haemorrhage: monitoring with thromboelastography, laboratory analyses or both? Int J Obstet Anesth. 2014;23(1):10-17. PMID: 24182438

52. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol. 2005;27(2):81-90. PMID: 15839912

53. Whiting D, DiNardo JA. TEG and ROTEM: technology and clinical applications. Am J Hematol. 2014;89(2):228-232. PMID: 24147752

54. McCrath DJ, Cerboni E, Frumento RJ, et al. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005;100(6):1576-1583. PMID: 15920146

55. Görlinger K, Fries D, Dirkmann D, et al. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. Transfus Med Hemother. 2012;39(2):104-113. PMID: 22577410

56. Weber CF, Görlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012;117(3):531-547. PMID: 22776887

57. American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology. 2015;122(2):241-275. PMID: 25545654

58. Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013;30(6):270-382. PMID: 23535722

59. Munoz M, Stensballe J, Dupont C, et al. Early prevention and treatment of postpartum haemorrhage: FIGO recommendations. Int J Gynaecol Obstet. 2022;158(3):531-543. PMID: 35751490

60. Sentilhes L, Vayssière C, Deneux-Tharaux C, et al. Postpartum hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). Eur J Obstet Gynecol Reprod Biol. 2016;198:156-161. PMID: 26773249

61. Mavrides E, Allard S, Chandraharan E, et al. on behalf of the Royal College of Obstetricians and Gynaecologists. Prevention and management of postpartum haemorrhage. BJOG. 2016;124(5):e106-e149. PMID: 28133797

62. Weeks AD. The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go to from here? BJOG. 2015;122(2):189-192. PMID: 25510984

63. World Health Organization. WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: WHO; 2012. PMID: N/A

64. World Health Organization. WHO Guidelines for the Management of Postpartum Haemorrhage and Retained Placenta. Geneva: WHO; 2009. PMID: N/A

65. Abenhaim HA, Azoulay L, Kramer MS, et al. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. Am J Obstet Gynecol. 2008;199(1):49.e1-49.e8. PMID: 18295168

66. Clark SL, Hankins GD, Dudley DA, et al. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol. 1995;172(4 Pt 1):1158-1167. PMID: 7726261

67. Clark SL, Pavlova Z, Greenspoon J, et al. Squamous cells in the maternal pulmonary circulation. Am J Obstet Gynecol. 1986;154(1):104-106. PMID: 3946427

68. Conde-Agudelo A, Romero R. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol. 2009;201(5):445.e1-445.e13. PMID: 19646677

69. Davies S. Amniotic fluid embolus: a review of the literature. Can J Anaesth. 2001;48(1):88-98. PMID: 11195538

70. Gilbert WM, Danielsen B. Amniotic fluid embolism: decreased mortality in a population-based study. Obstet Gynecol. 1999;93(6):973-977. PMID: 10362165

71. Hankins GD, Snyder RR, Clark SL, et al. Acute hemodynamic and respiratory effects of amniotic fluid embolism in the pregnant goat model. Am J Obstet Gynecol. 1993;169(6):1432-1440. PMID: 8282261

72. Hankins GD, Snyder R, Dildy G, et al. Amniotic fluid embolism. An analysis of the national registry. Am J Obstet Gynecol. 1997;176(1 Pt 1):133. PMID: 9024110

73. Kramer MS, Rouleau J, Baskett TF, et al. Amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. Lancet. 2006;368(9545):1444-1448. PMID: 17055946

74. Moise KJ Jr, Bale RJ. Amniotic fluid embolism: a comprehensive review. Obstet Gynecol Surv. 2006;61(2):122-128. PMID: 16445134

75. Stolte L, van Kessel H, Seelen J, et al. Failure to produce the syndrome of amniotic fluid embolism by infusion of amniotic fluid and meconium into monkeys. Am J Obstet Gynecol. 1967;98(3):411-413. PMID: 4951225

76. Tuffnell DJ. United Kingdom amniotic fluid embolism register. BJOG. 2005;112(12):1625-1629. PMID: 16305587

77. Weiwen Y. Studies on the pathogenesis of amniotic fluid embolism. Chin Med J (Engl). 1984;97(8):581-585. PMID: 6508769

78. Clark SL. New concepts of amniotic fluid embolism: a review. Obstet Gynecol Surv. 2014;69(7):399-408. PMID: 25102356

79. Clark SL, Romero R, Dildy GA, et al. Proposed diagnostic criteria for the case definition of amniotic fluid embolism in research studies. Am J Obstet Gynecol. 2016;215(4):408-412. PMID: 27063446

80. Fitzpatrick KE, Tuffnell D, Kurinczuk JJ, Knight M. Incidence, risk factors, management and outcomes of amniotic fluid embolism: a population-based cohort and nested case-control study. BJOG. 2016;123(1):100-109. PMID: 25959221

81. Gist RS, Stafford IP, Leibowitz AB, et al. Amniotic fluid embolism. Anesth Analg. 2009;108(5):1597-1602. PMID: 19372336

82. O'Shea A, Eappen S. Amniotic fluid embolism. Int Anesthesiol Clin. 2007;45(1):119-131. PMID: 17366651

83. Tamura N, Kimura S, Farhana M, et al. Amniotic fluid embolism: Pathophysiology from the perspective of pathology. J Obstet Gynaecol Res. 2017;43(4):627-632. PMID: 28176348

84. Kaufman DW, Watson J, Rosenberg L, et al. The drug etiology of agranulocytosis and aplastic anemia. Am J Hematol. 1992;40(1):43-48. PMID: 1575017

85. Rebarber A, Lonser R, Jackson S, et al. The safety of intraoperative autologous blood collection and autotransfusion during cesarean section. Am J Obstet Gynecol. 1998;179(3):715-720. PMID: 9757972

86. Waters JH, Biscotti C, Potter PS, et al. Amniotic fluid removal during cell salvage in the cesarean section patient. Anesthesiology. 2000;92(6):1531-1536. PMID: 10839904

87. Catling SJ, Williams S, Fielding AM. Cell salvage in obstetrics: an evaluation of the ability of cell salvage combined with leukocyte depletion filtration to remove amniotic fluid from operative blood loss at cesarean section. Int J Obstet Anesth. 1999;8(2):79-84. PMID: 15321325

88. Gilson GJ, Samaan S, Crawford MH, et al. Changes in hemodynamics, left ventricular mechanics, and oxygen dynamics during massive intraoperative hemorrhage in dogs with and without autologous blood transfusion. Am Surg. 1993;59(4):248-255. PMID: 8453096

89. Goodnough LT, Shander A. Blood management. Arch Pathol Lab Med. 2007;131(5):695-701. PMID: 17451965

90. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet. 2003;361(9352):161-169. PMID: 12531575

91. Goodnough LT, Shander A. Patient blood management. Anesthesiology. 2012;116(6):1367-1376. PMID: 22504125

92. Gross I, Seiffer C, Popovsky MA. Autologous blood transfusion and collection in the perioperative period. Am J Clin Pathol. 1989;92(4):457-460. PMID: 2679135

93. Helm RE, Klemperer JD, Rosengart TK, et al. Intraoperative autologous blood donation preserves red blood cell mass but does not decrease postoperative bleeding. Ann Thorac Surg. 1996;62(5):1431-1441. PMID: 8895332

94. Munoz M, Gomez-Ramirez S, Martin-Montanez E, et al. Perioperative anemia management in colorectal cancer patients: a pragmatic approach. World J Gastroenterol. 2014;20(8):1972-1985. PMID: 24627529

95. Shander A, Goodnough LT. Why an alternative to blood transfusion? Crit Care Clin. 2009;25(2):261-277. PMID: 19343112